Rumi Viro’s technology is a powerful high-throughput platform to generate miniaturized synthetic organs that mimic organs that are highly susceptible to viral infection, at high-speed. We have an unparalleled ability to track viral infection in thousands of synthetic mini organs at a time. With our machine learning algorithm, we are able to identify therapeutics that inhibit the infection, replication and transmission of viruses, which allows us to predict the therapeutic benefit that a drug could have on patients exposed to the virus.
We can mimic the development of human organs and the complex biology behind this process.
Rumi Viro’s technology is based on a collaboration by Dr. Ali Brivanlou and Dr. Charles Rice, the heads of the Virology and Stem Cell Biology Laboratories at Rockefeller University, who worked together to combine the disciplines of stem cell biology and virology. This fusion of stem cell biology and virology has resulted in a transformative approach of using human embryonic stem cells that self-organize to generate miniature organs. These organs recapitulate human organs both in morphology and gene expression profiles.
We can mimic the entire lifecycle of viral infection in human tissues.
Rumi Viro has already identified phenotypic signatures associated with multiple viruses including coronaviruses as well as influenza and parainfluenza viruses. We have also identified compounds and antibodies capable of neutralizing infection by these viruses and inhibiting virus-induced pathology.
We can apply Breakthrough 1 and 2 in thousands of mini organs.
Rumi Viro’s technology has created a unique and transformative screening platform for viral infectious diseases to identify potential treatments through the application of high throughput methods to create and screen thousands of nearly identical mini organs. No other existing platform can achieve the qualitative and quantitative level of resolution obtained with our technology.
We can achieve unbiased analysis using deep neural networks to estimate the toxicity and efficacy of each compound tested.
The Rumi Viro technology applies artificial intelligence to deconvolute the phenotypes associated with the ongoing interaction between viruses and their target human tissues during their viral life cycle when treated with potential therapeutics, allowing us to perform antiviral drug discovery at unprecedented precision, sensitivity and scale. Thus Rumi Viro technology can be applied to solve challenges in the drug discovery process for infectious diseases.
Rumi Viro’s platform outperforms existing drug discovery technologies
In addition to its groundbreaking work with COVID-19, the Rumi Viro platform will provide numerous benefits and opportunities versus the current landscape used by large pharmaceutical companies.
Our platform offers numerous transformative benefits to any company interested in developing drugs to treat infectious diseases, including the following:
The most promising path to achieve predictable success:
Our platform offers numerous transformative benefits to any company interested in developing drugs to treat genetic diseases, including the following: